10-QPeriod: Q1 FY2005

DEXCOM INC Quarterly Report for Q1 Ended Mar 31, 2005

Filed May 4, 2005For Securities:DXCM

Summary

DexCom, Inc. (DXCM) filed its quarterly report for the period ended March 31, 2005. This filing is significant as it covers the period immediately following the company's initial public offering (IPO) on April 13, 2005. As such, it provides investors with a crucial early look at the company's financial standing and operational performance post-IPO, although detailed comparative results for the current quarter against prior periods may be limited due to the recency of its public trading status. Investors should pay close attention to the financial statements and Management's Discussion and Analysis (MD&A) for insights into revenue generation, cost structures, and cash flow. Given DexCom's focus on developing continuous glucose monitoring (CGM) technology, the report will likely highlight progress in product development, regulatory approvals, and early market penetration. Understanding the company's cash position and burn rate will be critical for assessing its ability to fund future growth initiatives.

Key Highlights

  • 1This 10-Q covers the quarterly period ended March 31, 2005, with the company having completed its IPO on April 13, 2005.
  • 2The filing includes unaudited Balance Sheets as of December 31, 2004, and March 31, 2005.
  • 3Statements of Operations and Cash Flows are provided for the three months ended March 31, 2004 and 2005, as well as a cumulative period from inception.
  • 4Management's Discussion and Analysis (MD&A) section is included, which is critical for understanding the company's financial condition and results of operations.
  • 5The company has indicated it is not yet an accelerated filer, consistent with its recent IPO.
  • 6As of April 26, 2005, 25,361,399 shares of common stock were outstanding.

Frequently Asked Questions

This 10-Q is significant because it is one of the first financial reports released by DexCom after its initial public offering (IPO) on April 13, 2005. It provides investors with an early look at the company's financial health and operational performance in the period immediately following its debut as a publicly traded entity.

The report includes unaudited financial statements such as Balance Sheets as of December 31, 2004, and March 31, 2005. It also provides Statements of Operations and Cash Flows for the three months ended March 31, 2004 and 2005, and a longer cumulative period since the company's inception.

DexCom is not considered an accelerated filer because it has recently commenced trading following its IPO on April 13, 2005, and has not yet met the criteria (generally, having been subject to the reporting requirements for at least 12 months and having a public float of $75 million or more) to be classified as such.

The 'Management’s Discussion and Analysis of Financial Condition and Results of Operations' section (Item 2) is the primary area within this 10-Q where investors can find management's perspective on the company's financial performance, trends, and outlook.